Stockscreener 앱 받기
0.4635
4.16%
0.0185
시장 영업 전:
.46
-0.0035
-0.76%
전일 마감가:
$0.445
열려 있는:
$0.44
하루 거래량:
83,602
Relative Volume:
0.26
시가총액:
$10.89M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+39.36%
1개월 성능:
-12.58%
6개월 성능:
-36.19%
1년 성능:
-71.21%
1일 변동 폭
$0.4093
$0.4661
1주일 범위
$0.32
$0.49
52주 변동 폭
$0.3176
$2.58
Cellyan Biotechnology Co Ltd Stock (HKPD) Company Profile
Compare HKPD vs MCK, COR, CAH, HSIC, AHG
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HKPD
Cellyan Biotechnology Co Ltd
|
0.4635 | 10.46M | 0 | 0 | 0 | 0.00 |
MCK
Mckesson Corp
|
785.43 | 91.29B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
281.46 | 54.76B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
227.72 | 53.02B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
81.21 | 9.24B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.21 | 993.78M | 14.85M | -136.07M | 7.25M | -0.4726 |
Cellyan Biotechnology Co Ltd 주식(HKPD)의 최신 뉴스
Cellyan Biotech (HKPD) Slides 7.6%, Testing Key Support at $0.39New Listing Stocks - newsline.com
Cellyan Biotechnology (NASDAQ: HKPD) files $200M shelf to sell shares, debt - Stock Titan
Cellyan Biotechnology (HKPD) director CHAN Kam Leung files initial Form 3 - Stock Titan
[Form 3] Cellyan Biotechnology Co., Ltd Initial Statement of Beneficial Ownership - Stock Titan
Cellyan Biotechnology (HKPD) Chief Strategy Officer listed with no Form 3 transactions - Stock Titan
Cellyan Biotechnology (HKPD) CFO Liu Shu files initial ownership Form 3 - Stock Titan
Cellyan Biotechnology (HKPD) director Zhou Mike Yao files initial Form 3 - Stock Titan
Cellyan Biotechnology (HKPD) director Wu Jingyan submits initial SEC Form 3 - Stock Titan
Cellyan Biotechnology (HKPD) CEO and director files Form 3 with no share transactions - Stock Titan
Cellyan Biotechnology (HKPD) Slumps 7.83%: Key Support at $0.50 Under PressureFibonacci Fan - The Legal Advocate
Cellyan Biotechnology (HKPD) Holds Steady Near Support After Marginal GainsAdvance Decline Volume - The Legal Advocate
Cellyan Biotechnology (HKPD) Drops 3.6% as Shares Approach Critical $0.50 SupportButterfly Setup - The Legal Advocate
Cellyan Biotechnology Faces Resistance at $0.57 After Recent DeclineIntraday Trade Ideas - The Legal Advocate
Cellyan (HKPD) quarterly earnings report shows no revenue, EPS data available amid biotechnology sector headwinds.Shared Buy Zones - Newser
What net volume Cellyan (HKPD)? (Smart Money Outflows) 2026-04-29Buy Signals - newser.com
What leverage Cellyan (HKPD)? | HKPD Latest Quarter Earnings: Cellyan logs zero revenue, advances key drug pipeline progressSocial Trading Insights - newser.com
HKPD Latest Quarter Earnings: Cellyan logs zero revenue, advances key drug pipeline progress - newsline.com
12 Industrials Stocks Moving In Friday's Pre-Market Session - Benzinga
HKPD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HKPD (Cellyan) posts 21.7 percent Q2 2025 revenue growth, shares drop 6.58 percent amid negative earnings.Dividend Increase Stocks - The Legal Advocate
Cellyan (HKPD) Stock: Is It Ready for Entry (Institutional Demand) 2026-04-18Index Investing - Cổng thông tin điện tử tỉnh Lào Cai
HKPD Technical Analysis & ETF Price Forecast - Intellectia AI
[EFFECT] Cellyan Biotechnology Co., Ltd SEC Filing - Stock Titan
HKPD Stock Analysis: Cellyan Biotechnology Co. Ltd gains 1.59% to trade at 0.57 dollar - newsline.com
12 Industrials Stocks Moving In Monday's Intraday Session - Benzinga
According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), the selling shareholders of Cellyan Biotechnology Co Ltd may sell up to 12.5 million Class A ordinary shares from time to time in the future. - Bitget
12.5M shares for resale — Cellyan Biotechnology (NASDAQ: HKPD) - stocktitan.net
Cellyan Biotechnology (HKPD) completes $6.5M private unit financing - Stock Titan
If You Invested $1,000 in Cellyan Biotechnology Co Ltd (HKPD) - Stock Titan
Cellyan Biotechnology Reports Lower Revenue and Profit in Latest Interim Results - TipRanks
Cellyan Biotechnology (HKPD) interim revenue and profit drop sharply in 2025 - Stock Titan
Cellyan Biotechnology Co., Ltd Reports Earnings Results for the Half Year Ended September 30, 2025 - marketscreener.com
HKPD Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
12 Industrials Stocks Moving In Tuesday's After-Market Session - Benzinga
PETS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cellyan Biotechnology receives Nasdaq bid price deficiency notice - MSN
Cellyan Biotechnology boosts share capital and completes name change after December AGM - MSN
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency - The Manila Times
Cellyan Biotechnology receives Nasdaq minimum bid price deficiency notice - Investing.com
Cellyan Biotechnology Hit With Nasdaq Bid-Price Deficiency Notice, Shares Remain Listed - TipRanks
12 Industrials Stocks Moving In Thursday's Pre-Market Session - Benzinga
Cellyan Biotechnology Co Ltd (NASDAQ:HKPD) - intelligentinvestor.com.au
Cellyan Biotechnology Co Ltd (NASDAQ: HKPD)Share Price - intelligentinvestor.com.au
Clinical Trial Supplies Company Evaluation Report 2025: Market Led by Thermo Fisher Scientific, Sharp Services, and Parexel Through End-to-End Capabilities Span Packaging, Logistics, Trial ManagementResearchAndMarkets.com - FinancialContent
Cellyan Biotechnology Co., Ltd: Dividend historical data and projections - MarketScreener
HKPD: Static price chart | Cellyan Biotechnology Co., Ltd | KYG6365B1041 - MarketScreener
Cellyan Biotechnology Co., Ltd: Shareholders Board Members Managers and Company Profile | KYG6365B1041 - MarketScreener
There was once a stone that lay deep in the heart of a flowing river.Stock Buy Signals & Get The Analyst Consensus With One Click - bollywoodhelpline.com
Technical Charts Suggest Momentum Shift in Silicon Rental Solutions LimitedMoving Average Crossovers & Free Get High Impact Recommendations - bollywoodhelpline.com
Hawa Engineers Limited Nearing Breakout Level After BounceMid Cap Growth Trends & Plan Your Future With Strategic Investing - bollywoodhelpline.com
Is there any way to Buy Stocks in US market from IndiaTechnical Resistance Breaks & Outstanding Portfolio Tips - bollywoodhelpline.com
Cellyan Biotechnology Co Ltd (HKPD) 재무 분석
Cellyan Biotechnology Co Ltd (HKPD)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
5.36%
2.63%
자본화:
|
볼륨(24시간):